See other companies on Otta
OneStudyTeam
Digital tools for clinical trials
- 201-500 employees
- Healthcare
- B2B
- SaaS
- Social Impact
- MedTech
- 33 Arch St, Boston, Massachusetts 02110, US
Jump to section
Company mission
To pave the way to faster, predictable, and more accessible clinical trials.
Insights
Otta's take
Sam Franklin
CEO of Otta
Clinical research remains a significant bottleneck on drug development. Much of this is due to the slow and unpredictable nature of patient enrolment. OneStudyTeam is tackling this problem with a platform that helps biopharma companies and research sites to enroll trials in three to four months instead of 18 months.
The company's tools are already being used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly & Company, and across a total of over 5,000 research sites across 65 countries. In 2022, OneStudyTeam invested $220 million into improving diversity in clinical trials. This is a strong indicator of the company’s future-facing outlook and its impressive financial backing.
The business is scaling fast, reaching Unicorn status with its Series C round in 2021. If this trajectory continues, OneStudyTeam could become one of the leading names in the pharmaceutical and healthcare industries.
Benefits
- Comprehensive health and wellness
- Generous parental leave
- Flexible paid time off
- 401(k) company match
Funding (last 2 of 5 rounds)
Apr 2022
$220m
SERIES D
Aug 2021
$220m
SERIES C
$477.6m
Total funding
This company has top investors
Founders
Ralph Passarella
(CEO)Founded Reify Health in 2012 whilst completing a PhD/MD at The Johns Hopkins University School of Medicine. Also Co-Founder and Board Member at Signal Vine.
Michael Lin
(Executive Chairman)Studied at The Johns Hopkins University School of Medicine. Also Co-founder at Signal Vine.
Articles
Jobs (4)
Software Engineering
Finance, Legal & Compliance